Cancer Clinical Trials Accrual: Missed Opportunities to Address Disparities and Missed Opportunities to Improve Outcomes for All by unknown
Cancer Clinical Trials Accrual: Missed Opportunities to
Address Disparities and Missed Opportunities to Improve
Outcomes for All
Lisa A. Newman, MD, MPH,1 Nathalie Kim Roff, MD,2 and Armin D. Weinberg, PhD2
1Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
2Baylor College of Medicine, 1709 Dryden, Houston, TX 77030, USA
Stewart et al.1 have implemented a clever strategy for
documenting the underrepresentation of racial/ethnic
minorities and older patients in surgical oncology
clinical trials. Their approach involved calculation of
an ‘‘enrollment fraction’’ (EF) for various subsets of
the American cancer patient population. Individual
EFs were computed as the ratio of National Cancer
Institute (NCI)-generated data on cooperative group
clinical trial accrual compared with Surveillance,
Epidemiology, and End Results Program-derived
cancer incidence data. The disappointing (but not
necessarily surprising) results from these analyses
demonstrated that EFs were substantially lower for
African American, Hispanic/Latino American, and
Asian/Paciﬁc Islander cancer patients (0.48%,
0.54%, and 0.59%, respectively) when compared with
white Americans (0.72%). Cancer patients age
75 years and older had an EF of 0.14%, in contrast
to an EF of 1.8% for patients aged 21 to 54, and
0.91% for those aged 55 and 64.
Race/ethnicity- and age-related disparities in sur-
gical oncology clinical trial accrual are potent exam-
ples of inequities the current American health care
system. The clinical trial mechanism represents the
most powerful weapon that the oncology community
possesses in the eﬀort to improve the standard of care
as well as survivorship for cancer patients. Diet,
comorbidities, lifestyle/culture, and socioeconomic
resources are all features that vary between and
within racial/ethnic communities, as well as by age
category. All of these factors can aﬀect cancer risk,
treatment, and survival. Our failure to account for
these variations by ensuring appropriate diversity in
the clinical trial patient population is truly a tragedy
because it represents a missed opportunity to under-
stand and eliminate cancer disparities.
As an extreme example, lack of diversity is analo-
gous to conducting a clinical trial of neoadjuvant
chemoradiation for rectal cancer where all of the
participants are college-educated, 45 year old Swed-
ish men who own a car and two homes, follow a strict
vegetarian diet, exercise daily, and have a perfect
body mass index. A trial of this design would obvi-
ously tell us very little about the eﬃcacy of neoad-
juvant chemoradiation in a population of obese
diabetic nursing home residents that happen to be
predominantly elderly immigrant women. Less dra-
matic diﬀerences between clinical trial participants
and the general cancer population will also put us at
risk for misunderstanding the safety proﬁles of
innovative cancer therapies.
The underrepresentation of minority racial/ethnic
groups in cancer clinical trials is magniﬁed when we
take a critical look at the accrual targets used by most
investigators. Most clinical trials aim for racial/ethnic
composition that reﬂects the demographics of the
general American population. This goal ignores the
fact that most clinical trials are designed for speciﬁc
cancer stages, and trials studying advanced-stage
disease tend to be prioritized. Minority racial-ethnic
patients are actually overrepresented among most
subsets of advanced-stage cancers. Therefore, we
should actually be aiming for accrual of substantially
Published online April 19, 2008.
Address correspondence and reprint requests to: LisaA.Newman,
MD, MPH; E-mail: lanewman@med.umich.edu
Published by Springer Science+Business Media, LLC  2008 The Society of
Surgical Oncology, Inc.
Annals of Surgical Oncology 15(7):1818–1819
DOI: 10.1245/s10434-008-9869-2
1818
higher proportions of these patients for clinical trials
that are designed to study advanced cancer. To ad-
dress this issue, the American College of Surgeons
Oncology Group (ACOSOG) Special Populations
Committee2 worked with the National Cancer Data
Base to develop organ- and stage-speciﬁc accrual
targets for breast, prostate, lung, and colorectal
cancer trials.
The missed opportunity to understand cancer dis-
parities through clinical trials research is an undeni-
able ﬂaw in oncology research. However, the more
fundamental problem is our dismally low accrual of
adult cancer patients from the general American
population onto clinical trials. Stewart et al. reported
an overall EF of only 0.68% for all adult patients
onto surgical trials for breast, prostate, colorectal,
and lung cancer. Work conducted by other investi-
gators has estimated that only 4% of all adult
American cancer patients participate in any type of
clinical trial. These very low accrual proportions
represent a frustrating barrier to advances in overall
cancer treatment and survivorship.
Clearly, we must do a better job of educating the
American public about the beneﬁts and safety of
clinical trial research; and we must make it easier for
the oncology community to provide their patients
with opportunities to enroll onto clinical trials.
Unfortunately, however, these eﬀorts frequently
counteract each other. Dense regulations and multi-
tiered review processes accompany every clinical trial,
with the intent of ensuring protection of human
subjects. These protections are essential, but they are
also costly and labor-intensive. The resulting imped-
iments are apparent with two important breast cancer
trials that were never completed. The ACOSOG
Z0011 trial was designed to answer a question that
has been debated for decades regarding the necessity
of a standard axillary lymph node dissection in all
cases of node-positive breast cancer. The Radiation
Therapeutics and Oncology Group (RTOG) con-
ducted a trial to determine whether whole-breast
radiation is necessary for all cases of ductal carci-
noma-in-situ managed by breast conservation. Both
of these trials were closed because of poor accrual
rates, and we therefore continue to recommend these
morbid and expensive locoregional therapies as the
standard of care. It is certainly possible that the slow
accrual rates were at least partially attributable to the
complexities involved with patient education and the
logistics of clinical trial registration.
There is deﬁnitely hope on the horizon in the form
of several innovative collaborative endeavors that
aim to correct our current clinical trial accrual deﬁ-
ciencies. Through the Patient Education, Patient
Advocate, and Special Populations Committees, the
ACOSOG has implemented a variety of aggressive
outreach programs for patients and physicians
regarding clinical trial participation in areas with a
high population of minorities to increase their par-
ticipation in clinical trials (http://www.acosog.org/).
The Education Network to Advance Cancer Clinical
Trials (ENACCT) explores the use of community-
based participatory research methodology for clinical
trials recruitment (http://www.enacct.org/). The
Eliminating Disparities in Clinical Trials (EDICT)
program brings together leaders to advance policy
solutions to disparities in clinical trials through which
change can occur at the federal government, state
government, and institutional levels, as well as public,
private, and/or nonproﬁt sectors (http://www.bcm.
edu/edict/home.html). Two complementary projects,
BackPack and CLAS-ACT, are developing helpful
methods that should be used by physicians,
researchers, and advocates to eliminate disparities in
clinical trials, speciﬁcally in recruitment, retention,
and return.
The work of Stewart et al. highlights deﬁciencies in
surgical oncology clinical trial research programs.
Their research methods should be replicated by oth-
ers in analyzing accrual patterns to medical oncology,
radiation oncology, and imaging trials. We are likely
to see the same disappointing results, but we can only
move ahead by better deﬁning our starting point. To
truly redress disparities, we should not be satisﬁed by
only looking at those who are recruited onto trials.
We must also recognize the importance of ensuring
that we scrutinize with equal vigor the retention of
those accrued.
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